Publications by authors named "Alice H L Li"
Article Synopsis
- Current treatments for chronic hepatitis B virus (HBV) control viral levels but do not cure the infection or significantly lower viral protein production like surface antigen (HBsAg).
- ARB-1740 is a promising new RNA interference agent that has shown the ability to reduce HBV RNA and inhibit various viral proteins, making it effective against multiple strains of HBV.
- When combined with other treatments, ARB-1740 enhances liver HBsAg reduction and boosts the body's immune response, showing potential for curing HBV in the future.
AB-423 is a member of the sulfamoylbenzamide (SBA) class of hepatitis B virus (HBV) capsid inhibitors in phase 1 clinical trials. In cell culture models, AB-423 showed potent inhibition of HBV replication (50% effective concentration [EC] = 0.08 to 0.
View Article and Find Full Text PDF